TNX-901 is a drug being tested at National Jewish Medical and Research Center and other locations across America. It is believed that the drug may prevent reactions to small amounts of peanuts, such as reminant in foods.
The U.S. Food and Drug Administration (FDA) has "fast-tracked" the drug. A drug is given fast-track status if it meets a medical need not currently being met by any medication.
It is made by a Houston-based company called Tanox; there is a legal dispute against this lab that the drug is based on the same anti-asthma sciences paid for by Genentech and Novartis.